Recent Company News

• 09:17 AM ET Mar 16, 2026
  

  StreetAccount Summary - US Pre-market trading update

• 07:07 AM ET Apr 22, 2026
  

  NovaBridge appoints Mark Hagler as President and Chief Commercial Officer ($2.57, 0.00)

• 07:34 AM ET Apr 20, 2026
  

  Biogen enters into agreement to acquire TJ Biopharma's rights to felzartamab in the Greater China region ($177.35, 0.00)

• 06:55 PM ET Apr 16, 2026
  

  NovaBridge Appoints Emmett T. Cunningham, Jr., MD, PhD, MPH as Vice Chairman of the Board

• 04:53 PM ET Apr 07, 2026
  

  NovaBridge Biosciences reports FY EPADS ($0.48) vs year-ago ($0.61) ($2.48, 0.00)

• 11:11 AM ET Apr 02, 2026
  

  StreetAccount Summary - US unusual volume traders

• 08:32 AM ET Mar 16, 2026
  

  StreetAccount Summary - US Pre-market trading

• 07:02 AM ET Mar 16, 2026
  

  NovaBridge announces productive FDA Type B meeting on potential accelerated approval pathway for givastomig in gastric cancer ($2.83, 0.00)